Future efforts should focus on multi‐target combination strategies (e.g., STING inhibitors co‐administered with Aβ/tau drugs) and dynamically deciphering pathway alterations across AD stages to advance personalized treatment approaches. Here, MAPT is linked to Alzheimer disease.